Guardant Health study finds blood tests help assess recurrence risk after colorectal cancer metastasis surgery
GH•Guardant Health said results from a 130-patient Japanese study showed that combining its liquid biopsy tests improved recurrence-risk assessment after surgery for colorectal cancer metastases and identified three risk groups. The findings require prospective validation before informing treatment decisions.
1. Study findings
The PRECISION study paired pretreatment Guardant360 Liquid genomic profiling with postoperative Guardant Reveal testing for residual cancer in 130 patients in Japan. Combined testing identified three distinct recurrence-risk groups, potentially supporting more personalized treatment strategies. The findings require prospective validation in an interventional study before they can inform treatment decisions.
